Billiontoone, Inc. (NASDAQ:BLLN – Get Free Report) insider Thomas Lynch sold 35,112 shares of the business’s stock in a transaction dated Thursday, September 17th. The shares were sold at an average price of $110.33, for a total value of $3,873,906.96. Following the completion of the sale, the insider owned 700 shares in the company, valued at $77,231. This represents a 98.05% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Billiontoone Stock Performance
NASDAQ BLLN traded down $2.06 during trading on Monday, hitting $103.86. 412,675 shares of the company’s stock traded hands, compared to its average volume of 596,416. The company has a debt-to-equity ratio of 0.17, a quick ratio of 11.31 and a current ratio of 11.69. The stock has a market capitalization of $4.90 billion and a price-to-earnings ratio of 151.31. Billiontoone, Inc. has a 12-month low of $61.96 and a 12-month high of $150.44. The business has a 50 day moving average of $109.42 and a 200-day moving average of $97.24.
Billiontoone (NASDAQ:BLLN – Get Free Report) last posted its earnings results on Wednesday, August 5th. The company reported $0.15 earnings per share for the quarter, hitting the consensus estimate of $0.15. Billiontoone had a net margin of 8.04% and a return on equity of 9.96%. The firm had revenue of $109.45 million during the quarter. As a group, equities research analysts anticipate that Billiontoone, Inc. will post 0.83 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Wall Street Analysts Forecast Growth
Several equities analysts have recently weighed in on the company. Wall Street Zen cut Billiontoone from a “buy” rating to a “hold” rating in a research report on Saturday, August 8th. Weiss Ratings raised Billiontoone from a “sell (d)” rating to a “sell (d+)” rating in a report on Tuesday, June 23rd. JPMorgan Chase & Co. reduced their target price on Billiontoone from $145.00 to $130.00 and set an “overweight” rating for the company in a report on Thursday, August 6th. Canaccord Genuity Group assumed coverage on Billiontoone in a research report on Wednesday, September 2nd. They set a “buy” rating and a $120.00 price target on the stock. Finally, BTIG Research decreased their target price on shares of Billiontoone from $142.00 to $130.00 and set a “buy” rating on the stock in a report on Thursday, August 6th. Seven research analysts have rated the stock with a Buy rating, two have given a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $125.88.
Get Our Latest Stock Report on BLLN
Billiontoone Company Profile
BillionToOne, Inc is a molecular diagnostics company that develops blood-based tests designed to provide genetic and health information from small amounts of biological material. The company’s technology uses its proprietary quantitative counting template approach to improve the accuracy and sensitivity of molecular testing.
The company’s primary offerings include UNITY, a portfolio of prenatal genetic tests. These services support screening for chromosomal conditions, single-gene disorders and carrier status, and are designed to help healthcare providers assess fetal and maternal genetic risks using a maternal blood sample.
Featured Articles
- Five stocks we like better than Billiontoone
- Can Bloom Energy Pop the Top Off AI’s Massive Energy Bottleneck?
- Coach’s Momentum Powers Tapestry Despite the Stock’s Sharp Pullback
- AI Is Reshaping SaaS—These 2 Software ETFs Offer Different Ways to Play It
- Insiders Signal Deep Value In DICK’s Sporting Goods
Receive News & Ratings for Billiontoone Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Billiontoone and related companies with MarketBeat.com's FREE daily email newsletter.
